Miao Xianyuan, Guo Qiusheng, Pan Zhiwen, Xu Xiaohong, Shao Xiying, Wang Xiaojia
The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.
Department of Clinical Laboratory, Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Hangzhou, China.
Ann Transl Med. 2021 Aug;9(16):1332. doi: 10.21037/atm-21-3848.
Follicular regulatory T cells (Tfr) are a subset of regulatory T cells (Tregs) that suppress the humoral immune response in the germinal center. They are associated with increased rates of disease stabilization and decreased autoantibody levels in a variety of tumor and autoimmune diseases. The binding of T-cell immunoglobulin mucin 3 (TIM-3) and its ligand on the surface of Tfr cells could result in the depletion of T lymphocytes and the termination of the immune response mediated by helper T cell 1. However, the role of Tfr cells in breast cancer (BC) remains unclear.
In this study, we detected the expression of CD4+CXCR5+Foxp3+Tfr cells in the peripheral blood of 35 BC patients and 30 healthy control patients by flow cytometry, and analyzed the relationship between Tfr cells and the clinical characteristics of patients. In addition, the expression of TIM-3 on the surface of Tfr cells in 6 triple-negative BC (TNBC) patients was further investigated using mass spectrometry.
We found a significant increase in Tfr cells in BC patients compared to healthy control patients (23.47%±9.70% . 10.99%±4.68%; P=0.001). Notably, the increase was more significant in early stage than advanced stage TNBC patients (28.52%±10.75% . 18.69%±5.19%; P=0.006), and there was a negative correlation between Tfr cells and serum lactate dehydrogenase (LDH) in early stage TNBC patients (r=-0.585; P=0.008). Additionally, we found that the expression of Tfr cells was higher in TNBC patients than luminal BC patients (28.25%±10.11% . 18.5%±8.15%; P=0.028); however, there was no significant difference in expression in hormone receptor positive (HR+) BC and hormone receptor negative (HR-) BC (P=0.141) patients. Notably, the surface of Tfr cells of TNBC patients had higher levels of TIM-3 expression than those of healthy control patients (3.93±0.92 . 2.65±0.15, respectively; t=-3.02; P<0.05), which the mass spectrometry showed were positively correlated with the intracellular Foxp3 expression of Tfr cells (r=0.82; P=0.036).
Our results suggest that circulating Tfr cells and the expression of TIM-3 were significantly increased in BC patients, which were related to stage and histological type, and may be involved in the pathogenesis of BC.
滤泡调节性T细胞(Tfr)是调节性T细胞(Tregs)的一个亚群,可抑制生发中心的体液免疫反应。在多种肿瘤和自身免疫性疾病中,它们与疾病稳定率增加和自身抗体水平降低有关。Tfr细胞表面的T细胞免疫球蛋白粘蛋白3(TIM-3)与其配体的结合可能导致T淋巴细胞耗竭,并终止辅助性T细胞1介导的免疫反应。然而,Tfr细胞在乳腺癌(BC)中的作用仍不清楚。
在本研究中,我们通过流式细胞术检测了35例BC患者和30例健康对照患者外周血中CD4+CXCR5+Foxp3+Tfr细胞的表达,并分析了Tfr细胞与患者临床特征之间的关系。此外,使用质谱进一步研究了6例三阴性乳腺癌(TNBC)患者Tfr细胞表面TIM-3的表达。
我们发现,与健康对照患者相比,BC患者的Tfr细胞显著增加(23.47%±9.70%对10.99%±4.68%;P=0.001)。值得注意的是,早期TNBC患者的增加比晚期更显著(28.52%±10.75%对18.69%±5.19%;P=0.006),并且早期TNBC患者的Tfr细胞与血清乳酸脱氢酶(LDH)之间存在负相关(r=-0.585;P=0.008)。此外,我们发现TNBC患者的Tfr细胞表达高于管腔型BC患者(28.25%±10.11%对18.5%±8.15%;P=0.028);然而,激素受体阳性(HR+)BC和激素受体阴性(HR-)BC患者的表达没有显著差异(P=0.141)。值得注意的是,TNBC患者Tfr细胞表面的TIM-3表达水平高于健康对照患者(分别为3.93±0.92对2.65±0.15;t=-3.02;P<0.05),质谱显示其与Tfr细胞的细胞内Foxp3表达呈正相关(r=0.82;P=0.036)。
我们的结果表明,BC患者循环中的Tfr细胞和TIM-3表达显著增加,这与分期和组织学类型有关,可能参与了BC的发病机制。